Chemicals & Allied Products · SIC 2800

BIOLARGO, INC.

BLGO

Watch

Latest revenue

$1.1M

as of 2026-03-31

Latest net income

as of 2026-03-31

Net margin

as of 2026-03-31

Price · 5Y

-2.7% / yr 16.5 pts / yr vs S&P 500 12.7% total
Compare:

Live market

delayed ≤15 min
$0.15
6.40%
Market cap
$47.8M
Enterprise value
$47.8M
P/E (trailing)
Forward P/E
P/B
Dividend yield
0.0%
52-wk high
$0.23
52-wk low
$0.11
Beta
Shares out
320.9M

5-year trend

What this company does

AI

ITEM 1. BUSINESS USE OF FORWARD-LOOKING STATEMENTS IN THIS REPORT This annual report on Form 10-K for the year ended December 31, 2025 (the “Annual Report”) contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, included in this Annual Report regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. These forward-looking statements include, but are not limited to, predictions regarding: • our business plan; • the commercial viability of our technology and products incorporating…

AI summary unavailable — showing raw filing excerpt

Generated from BLGO's filing dated 2026-03-04

Key risks

AI

ITEM 1A. RISK FACTORS Our future results of operations, financial condition and liquidity and the market price for our securities are subject to numerous risks, many of which are driven by factors that we cannot control. The following cautionary discussion of risks, uncertainties and assumptions relevant to our business includes factors we believe could cause our actual results to differ materially from expected and historical results. Other factors beyond those listed below, including factors unknown to us and factors known to us which we have not currently determined to be material, could also adversely affect our business, results of operations, financial condition, prospects and cash…

AI summary unavailable — showing raw filing excerpt

Generated from BLGO's filing dated 2026-03-04

Profitability

Gross margin

43.9%

0.7%

Operating margin

-191.3%

685.3%

Leverage

Debt / equity

1.06×

462.5%

Long-term debt / equity

0.15×

149.7%

Debt / assets

51.4%

224.9%

Earnings tracker

QuarterRevenueYoYNet incomeYoYNet margin

Q1 2026

2026-03-31

$1.1M-65.9%

Q4 2025

2025-12-31

$616.0K-83.1%

Q3 2025

2025-09-30

$1.1M-74.6%

Q2 2025

2025-06-30

$2.8M-44.6%

Q1 2025

2025-03-31

$3.3M-31.3%

Q4 2024

2024-12-31

$3.7M

Q3 2024

2024-09-30

$4.4M+62.8%

Q2 2024

2024-06-30

$5.0M+246.7%

Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.

Industry trend

Chemicals & Allied Products · SIC 2800

No data yet for industry average

Your notes

Keep private notes on BLGO — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

Insider buying

$0

Insider selling

$0

Net activity

+$0

Distinct insiders

0

Open-market trades over the last 365 days.

Recent transactions

DateInsiderTypeSharesPriceValue

Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.

Who owns BLGO

Institutional value

$19.1K

Total shares held

117.8K

Distinct holders

1

+0 vs prior

As of

2026-03-31

Prior: 2025-12-31

Filers with $100M+ AUM disclose holdings 45 days after quarter end.

Top institutional holders

#ManagerSharesValueQoQ changeAction
1FIRST AMERICAN TRUST, FSB117.8K$19.1K+0 (+0.0%)No change

Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.

Top questions investors are asking

Coming once BLGO's latest filing finishes processing.